112 related articles for article (PubMed ID: 23092794)
1. Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review.
Mateo-Carrasco H; Gálvez-Contreras MC; Fernández-Ginés FD; Nguyen TV
Drug Metabol Drug Interact; 2012; 27(3):171-5. PubMed ID: 23092794
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
Bilgi N; Bell K; Ananthakrishnan AN; Atallah E
Ann Pharmacother; 2010 May; 44(5):926-8. PubMed ID: 20332334
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics and interactions of raltegravir].
Placeres Alsina MM; Tuset Creus M; Miró JM
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():23-8. PubMed ID: 19572422
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
6. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
7. [Secondary effects associated with raltegravir].
Gatell JM; Zamora L
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():34-9. PubMed ID: 19572424
[TBL] [Abstract][Full Text] [Related]
8. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
9. Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
Cao R; Hu Y; Wang Y; Gurley EC; Studer EJ; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Zhou H
J Pharmacol Exp Ther; 2010 Aug; 334(2):530-9. PubMed ID: 20472667
[TBL] [Abstract][Full Text] [Related]
10. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
11. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
13. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
[TBL] [Abstract][Full Text] [Related]
15. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
16. Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by a lamotrigine-ginseng drug interaction.
Myers AP; Watson TA; Strock SB
Pharmacotherapy; 2015 Mar; 35(3):e9-e12. PubMed ID: 25756365
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.
de Castro N; Braun J; Charreau I; Lafeuillade A; Viard JP; Allavena C; Aboulker JP; Molina JM;
AIDS Res Ther; 2016; 13():17. PubMed ID: 27042193
[TBL] [Abstract][Full Text] [Related]
18. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.
Gray J; Young B
AIDS Patient Care STDS; 2009 Sep; 23(9):689-90. PubMed ID: 19663717
[No Abstract] [Full Text] [Related]
19. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
Croce F; Vitello P; Dalla Pria A; Riva A; Galli M; Antinori S
Int J STD AIDS; 2010 Nov; 21(11):783-5. PubMed ID: 21187364
[TBL] [Abstract][Full Text] [Related]
20. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Vispo E; Fernández-Montero JV; Labarga P; Barreiro P; Soriano V
AIDS; 2013 Apr; 27(7):1187-8. PubMed ID: 23739226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
